Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.63) per share. This is a 78.93 percent increase over losses of $(2.99) per share from the same period last year.
Paycor Sees Q1 Sales $89M-$90M, FY22 Sales $396M-$400M
Business Outlook
Based on information as of today, August 31, 2021, the Company is issuing the following financial guidance:
Quarter Ending September 30, 2021:
Total revenue in the range of $89.0 million